This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Cooperative Agreement award of $998,921 to Reselute, Inc. aims to develop a novel antibiotic-releasing intramedullary nail for treating fracture-related infections. The product will provide local antibiotic delivery at the fracture site to improve healing and reduce infection risks associated with severe traumatic bone fractures. The project scope includes completing preliminary testing, developing the manufacturing process, and conducting initial safety testing in an animal model. Upon successful completion, the company plans to advance the device to first-in-human clinical trials toward eventual regulatory approval. This award supports the translation of scientific discoveries into a practical medical technology solution to address a significant clinical challenge.
Generated 3/18/25, 3:14 AM